WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced data from its Phase 2 clinical trial of NXN-188 in patients with migraine. In the study, patients experiencing migraine with aura, which represents over 7 million patients in the US, achieved sustained relief from their headaches, representing a potentially differentiated treatment profile from current migraine therapies. These data were presented in a session at the European Headache and Migraine Trust International Congress in London.
